151 related articles for article (PubMed ID: 36863395)
21. Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis.
Ihaddadene R; Le Gal G; Delluc A; Carrier M
Thromb Res; 2014 Jul; 134(1):93-5. PubMed ID: 24835673
[TBL] [Abstract][Full Text] [Related]
22. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
Huisman MV; Bounameaux H
Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
[TBL] [Abstract][Full Text] [Related]
23. [Drug therapy of deep venous thrombosis].
Bounameaux H
Ther Umsch; 1996 Apr; 53(4):272-6. PubMed ID: 8658349
[TBL] [Abstract][Full Text] [Related]
24. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
Young AM; Marshall A; Thirlwall J; Chapman O; Lokare A; Hill C; Hale D; Dunn JA; Lyman GH; Hutchinson C; MacCallum P; Kakkar A; Hobbs FDR; Petrou S; Dale J; Poole CJ; Maraveyas A; Levine M
J Clin Oncol; 2018 Jul; 36(20):2017-2023. PubMed ID: 29746227
[TBL] [Abstract][Full Text] [Related]
25. Human pancreatic tumors grown in mice release tissue factor-positive microvesicles that increase venous clot size.
Hisada Y; Ay C; Auriemma AC; Cooley BC; Mackman N
J Thromb Haemost; 2017 Nov; 15(11):2208-2217. PubMed ID: 28834179
[TBL] [Abstract][Full Text] [Related]
26. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
Akl EA; Kahale L; Neumann I; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
Cochrane Database Syst Rev; 2014 Jun; (6):CD006649. PubMed ID: 24945634
[TBL] [Abstract][Full Text] [Related]
27. Efficiency and safety evaluation of prophylaxes for venous thrombosis after gynecological surgery.
Yu R; Nansubuga F; Yang J; Ding W; Li K; Weng D; Wu P; Chen G; Ma D; Wei J
Medicine (Baltimore); 2020 Jun; 99(25):e20928. PubMed ID: 32569239
[TBL] [Abstract][Full Text] [Related]
28. Anticoagulation Practice in Patients with Cancer-Associated Thrombosis: Insights from GeCAT, a German Prospective Registry Study.
Klamroth R; Sinn M; Pollich C; Bischoff S; Lohneis A; Orlovic AM; Wisłocka L; Habbel P; de Wit M; Späth-Schwalbe E; Scholz CW; Riess H
Oncol Res Treat; 2022; 45(4):178-185. PubMed ID: 34963120
[TBL] [Abstract][Full Text] [Related]
29. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
Akl EA; Rohilla S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann HJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006649. PubMed ID: 18254108
[TBL] [Abstract][Full Text] [Related]
30. [Pulmonary Embolism Despite Rivaroxaban in an Obese Patient].
Schuh T; Stöllberger C
Dtsch Med Wochenschr; 2017 Oct; 142(20):1548-1551. PubMed ID: 29017215
[TBL] [Abstract][Full Text] [Related]
31. What are the pharmacotherapy options for treating venous thromboembolism in cancer patients?
Prandoni P; Piovella C; Filippi L; Vedovetto V; Dalla Valle F; Piccioli A
Expert Opin Pharmacother; 2014 Apr; 15(6):799-807. PubMed ID: 24548179
[TBL] [Abstract][Full Text] [Related]
32. Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism.
Arachchillage DR; Efthymiou M; Mackie IJ; Lawrie AS; Machin SJ; Cohen H
Thromb Res; 2015 Feb; 135(2):388-93. PubMed ID: 25555316
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study.
Signorelli JR; Gandhi AS
J Oncol Pharm Pract; 2019 Mar; 25(2):362-368. PubMed ID: 29157146
[TBL] [Abstract][Full Text] [Related]
34. Safety and effectiveness of argatroban versus heparin for preventing venous thromboembolism after lumbar decompressive surgery.
Guo Y; Zou Z; Jia L; Huang Z; Yun X; Xing G
Int J Surg; 2017 Aug; 44():324-328. PubMed ID: 28694001
[TBL] [Abstract][Full Text] [Related]
35. Low molecular weight heparin versus rivaroxaban in the treatment of venous thromboembolism in gastrointestinal malignancies.
Choe HK; De Sancho MT; Kim SS; Dai T; Shah MA
Blood Coagul Fibrinolysis; 2018 Mar; 29(2):227-230. PubMed ID: 29389673
[TBL] [Abstract][Full Text] [Related]
36. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
Cochrane Database Syst Rev; 2011 Apr; (4):CD006649. PubMed ID: 21491395
[TBL] [Abstract][Full Text] [Related]
37. Effect of rosuvastatin on risk markers for venous thromboembolism in cancer.
Ades S; Douce D; Holmes CE; Cory S; Prior S; Butenas S; Callas P; Cushman M
J Thromb Haemost; 2018 Jun; 16(6):1099-1106. PubMed ID: 29575637
[TBL] [Abstract][Full Text] [Related]
38. Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer.
Ueyama H; Miyashita H; Takagi H; Cruz C; Burger A; Briasoulis A; Kuno T
J Thromb Thrombolysis; 2021 Jan; 51(1):102-111. PubMed ID: 32458316
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE
Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed?
Khorana AA; Yannicelli D; McCrae KR; Milentijevic D; Crivera C; Nelson WW; Schein JR
Thromb Res; 2016 Sep; 145():51-3. PubMed ID: 27485998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
